Quality Of Life

The NICE Decision Support Unit and EEPRU have released updated Stata, Excel and R commands for mapping EQ-5D-3L data to the new EQ-5D-5L value set, giving UK HTA analysts a validated route to convert legacy three-level utility data ahead of NICE's adoption of the five-level value set.

🚀 What if room-temperature plasma could redefine remote patient care? The FDA has granted approval for this innovative technology, enabling safe, effective treatments beyond traditional clinical settings and expanding access for patients worldwide. Discover how this breakthrough is shaping the future of decentralized healthcare. #SyenzaNews #MedTech #HealthcareInnovation #innovation #DigitalTransformation

Can South Africa make the shingles vaccine affordable for the people who need it most? 💉 The article outlines the barriers to access for older adults and immunocompromised groups, reviews cost-effectiveness and budget-impact evidence, and offers practical policy options—like pooled procurement, tiered pricing, and inclusion in public immunization programs—to improve equity and long-term savings. Read the full piece to see the evidence-based recommendations and next steps for policymakers and stakeholders. #SyenzaNews #HealthEconomics #globalhealth #healthcarepolicy #costeffectiveness

Ready to rethink how pharmaceutical innovation pays off for Europe? 💡📈 New drugs and smarter R&D strategies are delivering measurable health benefits while boosting economic returns across manufacturing, investment, and market access — but only with the right policy incentives and collaboration between industry and payers. Read the full article to see which policy levers and investment approaches unlock the greatest returns for patients, companies, and economies. #SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #innovation

🩺 Could we finally delay the onset of Type 1 diabetes? NICE has recommended teplizumab for people at high risk (stage 2), marking a potential first disease‑modifying option that can postpone progression to clinical disease — a decision driven by trial benefit, patient selection and cost‑effectiveness considerations. Read the full #SyenzaNews analysis to understand what this means for clinicians, payers and patients — and how implementation might unfold. #SyenzaNews #pharmaceuticals #HealthEconomics #healthcarepolicy #costeffectiveness

Can Europe's new Biotechnology Act turn the continent into a global biotech powerhouse? 🔬🚀 The Act streamlines regulatory pathways, harmonizes rules across member states, and unlocks funding and public–private partnerships to help startups scale and attract investment. It’s a strategic move to boost R&D, manufacturing capacity, and Europe’s competitiveness in life sciences. Read the full article to see what this means for investors, founders, and health systems — and the concrete steps organizations should take next. #SyenzaNews #biotechnology #HealthTech #innovation #governance

Could expanded regulatory approval for OTC glucose monitors bring safer, easier diabetes management for children? 🩺 Regulators are widening pathways for over‑the‑counter pediatric glucose monitoring—promising improved access, greater caregiver autonomy, and new safety and labeling expectations that manufacturers and clinicians must navigate. The change also reshapes market access and commercial strategy for MedTech players. Read the full article to understand the regulatory details, clinical implications, and what stakeholders should do next. #SyenzaNews #medicaldevices #regulatoryaffairs #healthcarepolicy #MarketAccess

Could data-driven care pathways transform treatment for major depressive disorder? 🧠 This article outlines how treatment-pathway modeling uses patient data and simulation to identify optimal sequencing, improve remission rates, and guide resource allocation—balancing clinical outcomes with economic impact. It highlights practical implications for clinicians, payers, and policymakers seeking more personalized, cost-effective MDD care. Read the full analysis to explore the models, key findings, and next steps for implementation. #SyenzaNews #AIinHealthcare #HealthTech #innovation #costeffectiveness

Can participatory arts transform care in the Netherlands? 🎭💡 Dutch initiatives demonstrate that co-created arts projects with patients, caregivers and communities can boost wellbeing, reduce isolation, and embed person-centred care—offering practical evaluation methods and scalable models for health services. Read the full article to explore concrete examples, impact evidence, and policy recommendations for bringing participatory arts into mainstream care. #SyenzaNews #HealthcareInnovation #healthforall #innovation #healthcarepolicy

🌟 Have you noticed the rising importance of patient-reported outcomes in clinical trials? In a recent analysis of trials from 2008 to 2023, there's a striking trend—usage of patient-reported outcome measures (PROs) has nearly doubled, reflecting a significant shift towards patient-centered research. Tools like EQ-5D and PROMIS are leading the charge, emphasizing the importance of health-related quality of life data. Dive into this insightful article to explore how these trends are shaping the future of healthcare and decision-making! #SyenzaNews #HealthEconomics #ClinicalTrials #HealthcareInnovation

🔍 Are we on the brink of a new era for treating neurofibromatosis type 1? The recent approval of Koselugo (selumetinib) by the European Commission marks a transformative step in addressing the unmet medical needs of adult patients with inoperable plexiform neurofibromas. With the results from the KOMET Phase III trial highlighting a significant 20% objective response rate, this new oral treatment not only bridges a crucial gap but also provides hope for those previously limited to high-risk surgical interventions. Explore the full implications of this groundbreaking approval and what it means for the future of NF1 management. #SyenzaNews #pharmaceuticals #HealthcareInnovation

🚀 Are we on the brink of a diabetes breakthrough? A newly developed implantable glucose device from MIT could revolutionize diabetes management, providing an autonomous solution to prevent life-threatening hypoglycemic episodes. This innovative device combines continuous glucose monitoring with responsive hormone delivery, potentially transforming patient care by reducing the need for constant oversight. Curious about how this technology could reshape diabetes outcomes and healthcare economics? Dive into the full article for a closer look! #SyenzaNews #HealthTech #HealthEconomics #Innovation